

INCREMENTAL HEALTHCARE RESOURCE UTILIZATION AND COSTS IN U.S. PATIENTS WITH CUSHING'S DISEASE COMPARED WITH DIABETES AND POPULATION CONTROLS

Sun GH,¹ Neary MP,² Chang E,¹ Ludlam WH,² Broder MS¹

¹ Partnership for Health Analytic Research, LLC, Beverly Hills, CA, ² Novartis Pharmaceuticals Corporation, East Hanover, NJ

BACKGROUND

- Cushing's disease (CD) is a form of Cushing's syndrome (hypercortisolism) caused by overproduction of adrenocorticotropic hormone (ACTH) from a pituitary corticotroph adenoma.
- The estimated U.S. incidence is 8 cases per million population.¹
- CD is associated with substantial morbidity, ranging from hypertension, osteoporosis, cardiovascular disease, and opportunistic infections.²
- Healthcare costs and resource utilization for patients with CD have not been studied extensively.

OBJECTIVE

- To estimate the healthcare resource use and costs associated with Cushing's disease.

METHODS

Study Design and Patient Identification

- Matched cohort study using US insurance claims from the MarketScan® database from 1/1/2008 to 12/31/2012.
- Patients with CD** were defined using CD case-finding algorithm by Burton et al.³:
 - At least 1 claim with a diagnosis of Cushing's syndrome (CS) (ICD-9-CM 255.0); AND
 - At least 1 claim with a diagnosis of either pituitary neoplasm; pituitary disorder (e.g., hyperfunction); hypophysectomy; radiosurgery; or bilateral inferior petrosal sinus sampling
- Patients with DM** were selected from a 5% random sample of all enrollees with ≥2 claims of diabetes mellitus (ICD-9-CM: 250.x) and no claim of CS by ICD-9-CM code, thereby no claim of CD.
- Population-based controls** were selected from a 5% random sample of all database enrollees with no claim of CS by ICD-9-CM code, thereby no claim of CD.
- Patients without 1 year of continuous enrollment were excluded.
- CD patients were matched to DM and population-based controls by age, gender, region, and year in a 1:2 ratio.

Study Measures

- All study measures were based on a 1-year observation period.
- Demographics: age, sex, geographic region
- Charlson Comorbidity Index (CCI) and number of chronic conditions
- Complications related to CD: cardiovascular disease/stroke, depression/anxiety, DM, kidney stones, infections, osteoporosis, vertebral compression fractures
- Healthcare utilization: number of hospitalizations, emergency department (ED) visits, office visits, prescription fills
- Costs: total, pharmacy and non-pharmacy

Statistical Analysis

- We conducted pairwise comparisons between CD and DM patients and between CD and control patients.
- To analyze differences between cohorts, chi-square tests and t-tests were performed for categorical and continuous variables, respectively.
- Statistical analyses were performed in SAS® 9.4 (SAS Institute, Cary, NC).

RESULTS

- The study included 1,852 patients with CD: 3,704 matched DM controls and 3,704 matched population controls.
- Mean age was 42.9 years (SD 12.3) and 78.2% were female.
- Patients with CD had statistically significantly higher rates of all comorbidities of interest than both patients with DM (other than DM itself) and controls (**Table 1**).
- Patients with CD were hospitalized more frequently, visited the ED more often, had more office visits, and filled more prescriptions than patients with DM (all p<.001; **Table 2**) or controls (all p<.001; **Table 2**)
- Mean total healthcare costs for patients with CD were \$26,269, versus \$12,282 for those with DM (p<.001) and \$5,869 for controls (p<.001; **Figure 1**).

TABLE 1. Patient Comorbidities

Comorbidity, n (%)	CD (n=1,852)	DM (n=3,704)	Control (n=3,704)
Cardiovascular disease/stroke	203 (11.0)	302 (8.2)	132 (3.6)
Depression/anxiety	457 (24.7)	502 (13.6)	415 (11.2)
Diabetes mellitus	486 (26.2)	3,704 (100.0)*	266 (7.2)
Kidney stones	81 (4.4)	76 (2.1)	56 (1.5)
Infections	391 (21.1)	609 (16.4)	424 (11.4)
Osteoporosis	156 (8.4)	51 (1.4)	49 (1.3)
Vertebral compression fractures	17 (0.9)	5 (0.1)	5 (0.1)

* By definition, patients with DM were required to have a claim-based diagnosis of DM.


p<.001 for all comparisons (CD vs. DM and CD vs. control).

TABLE 2. Annual Healthcare Utilization

No. of inpatient hospitalizations, n (%)	CD (n=1,852)	DM (n=3,704)	Control (n=3,704)
0	1,495 (80.7)	3,296 (89.0)	3,497 (94.4)
1	226 (12.2)	324 (8.7)	176 (4.8)
2	74 (4.0)	55 (1.5)	25 (0.7)
3+	57 (3.1)	29 (0.8)	6 (0.2)
No. of ED visits, n (%)			
0	1,381 (74.6)	2,921 (78.9)	3,173 (85.7)
1	281 (15.2)	514 (13.9)	395 (10.7)
2	107 (5.8)	154 (4.2)	85 (2.3)
3+	83 (4.5)	115 (3.1)	51 (1.4)
No. of office visits, mean ± SD	19.1±17.5	10.7±11.3	7.1±9.7
No. of prescription fills, mean ± SD	51.7±48.6	42.7±34.1	20.5±23.6

p<.001 for all comparisons (CD vs. DM and CD vs. control).

FIGURE 1. Mean Annual Healthcare Costs



LIMITATIONS

- Total healthcare costs for controls may be over-estimated, since healthy controls not having claims would not be included in the claims database.
- There are no ICD-9-CM codes specific to CD. The CD algorithm has been published previously, but not validated using medical records.
- Insurance claims are collected for payment, not research.
- Study only included patients with commercial insurance.

CONCLUSIONS

- The total healthcare cost of CD care was observed to be more than double the cost for diabetic patients and quadruple the cost for population-based controls.
- Our study highlights two potential drivers of this increased cost: higher rates of comorbidities seen in patients with CD, and CD surgical care, a key component of non-pharmacy costs.
- Delay in CD diagnosis, which may prolong symptoms, is another possible cause of increased cost in patients with CD.

References

- Broder MS, et al. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States. *Pituitary*. 2014 May 7. [Epub ahead of print]
- Colao A, et al. Managing Cushing's disease: the state of the art. *Endocrine*. 2014 Sep;47(1):9-20.
- Burton TM, et al. Development of an algorithm to identify Cushing disease patients in a US administrative claims database. Presented at: 13th International Pituitary Congress, June 12-14, 2013, San Francisco, CA.